Phillip Glotser, MD
Neurology · Tucson, AZNPI 1891100897
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 298 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,280 and has fallen 73.0% since, to $615 in 2022.
Across 298 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$961
- Otsuka America Pharmaceutical, Inc.$887
- Teva Pharmaceuticals USA, Inc.$415
- Alkermes, Inc.$371
- Sunovion Pharmaceuticals Inc.$350
- Bausch Health US, LLC$335
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,720100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 71 | $961 |
| Otsuka America Pharmaceutical, Inc. | 53 | $887 |
| Teva Pharmaceuticals USA, Inc. | 24 | $415 |
| Alkermes, Inc. | 26 | $371 |
| Sunovion Pharmaceuticals Inc. | 22 | $350 |
| Bausch Health US, LLC | 21 | $335 |
| Indivior Inc. | 10 | $187 |
| Amgen | 8 | $177 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $139 |
| Eisai Inc. | 6 | $99 |
| Avanir Pharmaceuticals, Inc. | 6 | $96 |
| Jazz Pharmaceuticals Inc. | 5 | $90 |
| Lilly USA, LLC | 5 | $84 |
| Arbor Pharmaceuticals, Inc. | 5 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $75 |
| Vanda Pharmaceuticals Inc. | 4 | $72 |
| Novartis | 3 | $64 |
| Alfasigma USA, Inc. | 3 | $58 |
| Merck | 3 | $50 |
| Harmony Biosciences LLC | 2 | $31 |
| Almatica Pharma LLC | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Adlon Therapeutics L.p. | 1 | $12 |
| Lundbeck LLC | 1 | $12 |
How this compares
$4,720 in reported general payments places this provider in the 60th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 57 | $44,255 |
| Nurtec OdtRimegepant Sulfate | 28 | $37,250 |
| Dimethyl Fumarate | 13 | $34,023 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 26 | $25,010 |
| QuliptaAtogepant | 11 | $23,685 |
| UbrelvyUbrogepant | 16 | $14,818 |
| Dalfampridine ErDalfampridine | 30 | $13,335 |
| Pregabalin | 313 | $8,787 |
| Duloxetine Hcl | 242 | $7,711 |
| Levetiracetam | 173 | $3,974 |
| Gabapentin | 257 | $3,651 |
| Memantine Hcl | 101 | $3,228 |
| Lidocaine | 45 | $3,211 |
| Diclofenac Sodium | 67 | $3,051 |
| Lacosamide | 38 | $2,509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $961 | $38,50327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 388 neurology providers in Arizona.
Other neurology in Tucson
- Francisco ValdiviaTucson$137K
- Cynthia ReedTucson$111K
- Yeeck SimTucson$38K
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Nida LaurinScottsdale$969K
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.